We describe a case of a 46-year-old man in Missouri, USA, with newly diagnosed advanced HIV and PCR-confirmed mpox keratitis. The keratitis initially resolved after intravenous tecovirimat and penicillin for suspected ocular syphilis coinfection. Despite a confirmatory negative PCR, he developed relapsed, ipsilateral PCR-positive keratitis and severe ocular mpox requiring corneal transplant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210637 | PMC |
| http://dx.doi.org/10.3201/eid3007.240388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Atypical Mpox Presentation With a Large, Chronic Right Upper Eyelid Ulcerative Mass.
Ophthalmic Plast Reconstr Surg
December 2024
Department of Ophthalmic Plastic and Reconstructive Surgery, Dean A. McGee Eye Institute.
The global outbreak of Mpox has resurged, leading to a significant increase in cases across numerous countries. Mpox infections are associated with potential ophthalmologic complications, such as periorbital skin lesions, blepharoconjunctivitis, keratitis, and vision impairment. Here, we present a retrospective case report of an atypical Mpox in an HIV-positive patient with a persistent 5 × 5 cm ulcerated, round, plaque-like eyelid lesion refractory to multiple treatment regimens.
View Article and Find Full Text PDFOcular Complications of Mpox: Evolving Understanding and Future Directions.
Int Ophthalmol Clin
October 2024
Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE.
Mpox (formerly known as monkeypox), an infectious disease caused by the monkeypox virus (MPXV), has been endemic in regions of Central and Western Africa. In 2022, the global spread of the clade IIb MPXV led to a multinational outbreak, primarily affecting sexual transmission networks among men who have sex with men. Despite interventions, new cases have continued to emerge.
View Article and Find Full Text PDFMonkeypox-related ophthalmic disease (MPXROD): Monitoring the antiviral effect of tecovirimat with monkeypox virus detection in tear samples.
Eur J Ophthalmol
November 2024
Faculty of Medicine, University of Thessaly, Larissa, Greece.
Introduction: Although monkeypox-related ophthalmic disease (MPXROD) is rare, visual impairing complications have been reported. At present, tecovirimat is the standard-of-care antiviral treatment. In this MPXROD case, the effect of tecovirimat was assessed with PCR analysis of tear samples and concurrent monitoring of inflammation with laser flare photometry (LFP).
View Article and Find Full Text PDFMonkeypox-related ophthalmic disease.
Taiwan J Ophthalmol
April 2024
Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Article Synopsis
- Monkeypox, or Mpox, is a viral illness that has been spreading internationally since mid-2022, including cases in Taiwan.
- In a reported case, a man developed eye infections and skin symptoms related to Mpox, with tests confirming the presence of the virus in both his throat and skin lesions.
- Despite initial treatment that included antiviral and antibiotic medications, the patient's eye condition worsened, requiring additional treatments, but eventually the corneal lesion healed, leaving a scar.
Mpox Virus and its ocular surface manifestations.
Ocul Surf
October 2024
Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI, USA. Electronic address:
The Mpox virus (MPXV) is the causative agent of human Mpox disease - a debilitating rash illness similar to smallpox. Although Clade I MPXV has remained endemic to West and Central Africa, Clade II MPXV has been responsible for many outbreaks worldwide. The most recent outbreak in 2022 resulted from the rapid spread of a new clade of MPXV, classified into Clade IIb - a distinct lineage from the previously circulating viral strains.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!